The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 12, 2009
Filed:
Mar. 23, 2007
Benjamin R. Yerxa, Raleigh, NC (US);
Ward M. Peterson, Morrisville, NC (US);
Janet L. Rideout, Fuquay-Varina, NC (US);
William Pendergast, Durham, NC (US);
Benjamin R. Yerxa, Raleigh, NC (US);
Ward M. Peterson, Morrisville, NC (US);
Janet L. Rideout, Fuquay-Varina, NC (US);
William Pendergast, Durham, NC (US);
Inspire Pharmaceuticals, Inc., Durham, NC (US);
Abstract
The present invention provides a method of treating edematous retinal disorders. The method comprises administration of a pharmaceutical formulation comprising a hydrolysis-resistant P2Y receptor agonist to stimulate the removal of pathological extraneous fluid from the subretinal and retinal spaces and thereby reduce the accumulation of said fluid associated with retinal detachment and retinal edema. The P2Y receptor agonist can be administered with therapeutic and adjuvant agents commonly used to treat edematous retinal disorders. The present invention also provides a method of treating cystic fibrosis. The present invention further provides P-(2'-deoxycytidine 5′-)P-(uridine 5′-) tetraphosphate, tetra-(alkali metal) salts such as tetrasodium, tetralithium, tetrapotassium, and mixed (tetra-alkali metal) salts. The present further provides a pharmaceutical formulation comprising a P-(2′-deoxycytidine 5′-)P-(uridine 5′-) tetraphosphate, tetra-(alkali metal) salt, in a pharmaceutically acceptable carrier.